Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc., acquires rights to FDA-Approved ELYXYB™ in the U.S. and Canada for the acute treatment of migraine
ELYXYBTM is a first-line treatment and the only FDA-approved, ready-to-use oral solution for the acute…